On Monday, Shares of Nokia Corporation (NYSE:NOK), gained 0.87% to $6.96.
Nokia Corporation, aims to be an efficient resource allocator as it has decided to reduce 70 jobs from its technologies unit in Finland, a company’s spokeswoman Riitta Mard told on Wednesday. The company will reshape the organization as part of revision in its long-term strategy. The spokeswomen told that discussion has been started with the staff in order to implement the decision.
The unit, containing Nokia’s brand-licensing business and patents, has employed almost 400 in Finland and 650 workers globally. Last week, the company said that it has aligned with Microsoft, HP and Telefonica for partnership in workplace space and IT infrastructure.
The Finland Company said in a statement that the transformation is predictable to be finished within the first quarter of 2017. It added that the company would be in a distinctive position with having the new cloud based architecture in order to exploit the full potential of IT and telecommunications operations for greater agility, superior quality and quicker introduction of new IT services. The company has revealed no financial details concerning the deal.
Nokia Corporation, together with its auxiliaries, provides network infrastructure and related services in Finland, the United States, Japan, China, India, the Russian Federation, Germany, Taiwan, Indonesia, Italy, and internationally.
Shares of MannKind Corp. (NASDAQ:MNKD), inclined 10.14% to $4.40, during its last trading session, ongoing its rally from the preceding session on Friday.
Analysts at Jefferies issued a note Friday morning saying they see “good interest” for use of MannKind’s Afrezza drug.
Afrezza, the company’s signature drug, is an inhalable product to treat diabetes.
The firm reiterated its “buy” rating with a price target of $9 following its recent Afrezza survey.
Jefferies surveyed 56 endocrinologists and primary care physicians about their predictable use of Afrezza for diabetes.
The firm said in a note, In screening physicians, we found that 35% did not know about Afrezza. Those that did, however, predictable to use Afrezza more frequently than we had predictable, especially among type 1 diabetics.
MannKind Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes in the United States.
At the end of Monday’s trade, Shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), surged 15.26% to $11.03.
Achillion Pharmaceuticals, stated financial results for the three months ended March 31, 2015. For the first quarter of 2015, the Company stated a net loss of $19.3 million or $0.17 per share, contrast with a net loss of $16.1 million or $0.17 per share for the first quarter of 2014. Cash, cash equivalents, marketable securities and interest receivable as of March 31, 2015 were $275.9 million.
Complement Factor D Platform
- Achillion’s complement Factor D inhibition platform has formerly demonstrated in vitro complete suppression of the complement system with a single oral dose in non-human primates.
- To date, a subset of compounds has been advanced through primary and secondary pharmacology studies, synthesis and scale up, and certain IND-enabling studies.
- Achillion anticipates to make a regulatory submission by year-end 2015 that will enable the initiation of a first-in-human clinical trial to evaluate the safety of an orally-administered complement factor D inhibitor.
Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes anti-infective drug therapies in the United States and internationally. It focuses on developing combination therapies for the treatment of chronic hepatitis C (HCV) infection and drug-resistant bacterial infections.
Finally, Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), ended its last trade showing no change to $1.01.
On May 12, Lexicon Pharmaceuticals declared that the manuscript entitled “Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes” has been selected to present at the 75th Scientific Sessions of the American Diabetes Association (ADA) in Boston on June 6, 2015, at 9:00 a.m. Eastern Time. The presentation will be part of the 4th Annual Diabetes Care Symposium and will be featured in a special July issue of Diabetes Care. This high-level symposium represents a competition of manuscripts presented to the journal and dedicated to the theme of “Novel Clinical Interventions in Therapy That Impact the Administration of Diabetes.” The manuscript was selected from over 150 manuscripts that were presented for the competition and will be accessible online on June 6, 2015, at care.diabetesjournals.org.
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of human diseases. Its drug development programs comprise telotristat etiprate, an orally-delivered small molecule drug candidate, which is in Phase III clinical trials for the treatment of carcinoid syndrome.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
